Quantifying the value of multi-gene testing in resected early-stage lung adenocarcinoma.

CGP can identify driver alterations and accelerate the start of first-line therapy at recurrence and may also represent a cost-effective approach for avoiding futile adjuvantICI in patients with drivers that have historically lacked activity with ICI in metastatic disease.